September 23, 2020
The Japan arm of Sanofi said on September 18 that it has received Japanese regulatory approval for a subcutaneous pen formulation of Dupixent (dupilumab), an interleukin-4 receptor alpha antagonist. Dupixent is approved for the treatment of atopic dermatitis inadequately controlled...read more